基于AR-V7的临床决策 - Suppr

Suppr

超能文献

Clinical decision-making with AR-V7.

作者信息

Thoma Clemens

机构信息

Nature Reviews Urology, .

出版信息

Nat Rev Urol. 2019 Dec;16(12):694. doi: 10.1038/s41585-019-0259-2.

DOI:10.1038/s41585-019-0259-2

PMID:31690843

Abstract

摘要

相似文献

Clinical decision-making with AR-V7.

Nat Rev Urol. 2019 Dec;16(12):694. doi: 10.1038/s41585-019-0259-2.

AR-V7 detection guides treatment.

Nat Rev Clin Oncol. 2018 Sep;15(9):533. doi: 10.1038/s41571-018-0072-5.

Re: Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker with Outcomes and Survival in Castration-Resistant Prostate Cancer.

J Urol. 2016 Oct;196(4):1124. doi: 10.1016/j.juro.2016.07.066. Epub 2016 Jul 18.

Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.

Eur Urol. 2017 Jan;71(1):1-3. doi: 10.1016/j.eururo.2016.07.021. Epub 2016 Jul 26.

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.

Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14.

AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.

Prostate. 2018 Jun;78(8):576-582. doi: 10.1002/pros.23501. Epub 2018 Mar 5.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

[Study on the prediction of AR-V7 and CTC circulation in patients with metastatic, castration-resistant prostate cancer (mCRPC) : Correlation between common clinical outcome parameters (rPFS, OS), CTC changes, and AR-V7 status (androgen receptor splice variant 7) in patients with mCRPC on first-line therapy with abiraterone acetate (STAR-V7)-study AP 96/17 of the AUO].

Urologe A. 2017 Dec;56(12):1615-1617. doi: 10.1007/s00120-017-0528-8.

Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Ann Oncol. 2015 Sep;26(9):1859-1865. doi: 10.1093/annonc/mdv282. Epub 2015 Jun 27.

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

J Clin Oncol. 2019 May 1;37(13):1120-1129. doi: 10.1200/JCO.18.01731. Epub 2019 Mar 13.

引用本文的文献

The differential presence of human polyomaviruses, JCPyV and BKPyV, in prostate cancer and benign prostate hypertrophy tissues.

BMC Cancer. 2021 Oct 24;21(1):1141. doi: 10.1186/s12885-021-08862-w.

Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment.

Biomed Res Int. 2021 Jan 8;2021:6230826. doi: 10.1155/2021/6230826. eCollection 2021.

本文引用的文献

Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.

Eur Urol. 2020 Feb;77(2):170-177. doi: 10.1016/j.eururo.2019.08.020. Epub 2019 Oct 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验